TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30170828

Group type: EXPERIMENTAL
Intervention: Distal sizing strategy
Number of subjects: 37

Group type: COMPARATOR
Intervention: Proximal sizing strategy
Number of subjects: 37
Study: 29061161

Group type: EXPERIMENTAL
Intervention: Gene-based risk test with lung cancer risk score
Number of subjects: 67

Group type: COMPARATOR
Intervention: Control group with no risk score
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Gene-based risk test with 'very high' risk score
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Gene-based risk test with moderate risk score
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Gene-based risk test with above moderate risk score
Number of subjects: 67
Study: 25097030

Group type: EXPERIMENTAL
Intervention: Magnesium with metamizol
Number of subjects: 54

Group type: COMPARATOR
Intervention: Metamizol only
Number of subjects: 54
Study: 23426111

Group type: EXPERIMENTAL
Intervention: Store and forward teledermatology
Number of subjects: 392

Group type: COMPARATOR
Intervention: Conventional consultation process
Number of subjects: 392
Study: 20931294

Group type: EXPERIMENTAL
Intervention: Patient navigation intervention (telephone calls and reminder letters)
Number of subjects: 3895

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 3895
Study: 19132624

Group type: EXPERIMENTAL
Intervention: Cervical pessary
Number of subjects: 660

Group type: COMPARATOR
Intervention: No intervention (control)
Number of subjects: 660
Study: 16887416

Group type: EXPERIMENTAL
Intervention: Normal hospital diet plus 400 mL oral nutritional supplements
Number of subjects: 445

Group type: COMPARATOR
Intervention: Normal hospital diet plus placebo
Number of subjects: 445
Study: 15006266

Group type: EXPERIMENTAL
Intervention: 200 microg misoprostol orally
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 200 microg misoprostol intravaginally
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo orally
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo intravaginally
Number of subjects: 120
Study: 10696831

Group type: EXPERIMENTAL
Intervention: S-ketamine
Number of subjects: 8
Study: 9382540

Group type: EXPERIMENTAL
Intervention: Intracystic instillation with Epirubicin (arm A)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Oral administration with 5-FU (arm B)
Number of subjects: 56

Group type: COMPARATOR
Intervention: Combination of arm A and arm B (arm C)
Number of subjects: 56
Study: 1590682

Group type: EXPERIMENTAL
Intervention: Ceftazidime (100 mg/kg/day) plus co-trimoxazole (trimethoprim, 8 mg/kg/day; sulfamethoxazole, 40 mg/kg/day)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Chloramphenicol (100 mg/kg/day) plus doxycycline (4 mg/kg/day) and co-trimoxazole (trimethoprim, 8 mg/kg/day; sulfamethoxazole, 40 mg/kg/day)
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Ceftazidime plus co-trimoxazole
Number of subjects: 64

Group type: COMPARATOR
Intervention: Chloramphenicol plus doxycycline and co-trimoxazole
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Both regimens
Number of subjects: 64
Study: 2408417

Group type: EXPERIMENTAL
Intervention: Ketoconazole
Number of subjects: 63

Group type: COMPARATOR
Intervention: Griseofulvin
Number of subjects: 63
Study: 29958044

Group type: EXPERIMENTAL
Intervention: NutriSUS micronutrient fortification (Group A)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control (Group B)
Number of subjects: 25
Study: 29626074

Group type: EXPERIMENTAL
Intervention: Intensive statin therapy targeting LDL-C <70 mg/dL
Number of subjects: 5042

Group type: COMPARATOR
Intervention: Standard statin therapy targeting LDL-C 100-120 mg/dL
Number of subjects: 5042
Study: 27219266

Group type: EXPERIMENTAL
Intervention: Tangential excision followed by skin autografting 2 days after injury
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Tangential excision followed by skin autografting 14 days after injury
Number of subjects: 12

Group type: COMPARATOR
Intervention: No excision (control)
Number of subjects: 12
Study: 24435882

Group type: EXPERIMENTAL
Intervention: Caffeine (6 mg kg(‐1))
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 22788995

Group type: EXPERIMENTAL
Intervention: Imagined Social Situation Exercise (ISSE)
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Erotic story
Number of subjects: 226

Group type: EXPERIMENTAL
Intervention: Unstructured fantasy
Number of subjects: 226

Group type: COMPARATOR
Intervention: Neutral condition
Number of subjects: 226
Study: 20045360

Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) at 2/100 Hz
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Manual acupuncture (MA)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 36
Study: 18545187

Group type: EXPERIMENTAL
Intervention: ECC+ (3 sets of 6 repetitions at 40% 1RM concentric and 100% 1RM eccentric)
Number of subjects: 22

Group type: COMPARATOR
Intervention: TRAD (4 sets of 6 repetitions at 52.5% 1RM)
Number of subjects: 22
Study: 11579272

Group type: EXPERIMENTAL
Intervention: Prednisone (30 mg/day for 2 weeks)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 9553290

Group type: EXPERIMENTAL
Intervention: Intravenous indomethacin (0.2 mg/kg per dose every 12 to 24 hours for three doses)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Oral indomethacin
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: RDS infants
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Indomethacin treatment
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Indomethacin treatment (1 or 2 doses)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Overall closure rate
Number of subjects: 67
Study: 8067791

Group type: EXPERIMENTAL
Intervention: Prednisolone (2 mg/kg daily for 14 days, then 1 mg/kg on alternate days for 10 weeks)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 24
Study: 3054474

Group type: EXPERIMENTAL
Intervention: Amphetamine 10 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Amineptine 200 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Clonidine 150 mcg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 30738795

Group type: EXPERIMENTAL
Intervention: Vascular endothelial growth factor-targeted therapy
Number of subjects: 138

Group type: COMPARATOR
Intervention: Disease progression defined by RECIST 1.1 criteria
Number of subjects: 138
Study: 31422207

Group type: EXPERIMENTAL
Intervention: Surgery alone
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Surgery plus adjuvant concurrent chemoradiotherapy (CCRT)
Number of subjects: 85
Study: 28813259

Group type: EXPERIMENTAL
Intervention: Foster care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher quality of care and more stable placements
Number of subjects: 0
Study: 26376285

Group type: EXPERIMENTAL
Intervention: Support condition (reminders of supportive others)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (reminders of mere acquaintances)
Number of subjects: 0
Study: 23644091

Group type: EXPERIMENTAL
Intervention: Group 2 (n=52) with additional unexcitability (UE) to bipolar pacing at 10 mA and 2-ms pulse width
Number of subjects: 102

Group type: COMPARATOR
Intervention: Group 1 (n=50) with bidirectional block across the ablation line
Number of subjects: 102
Study: 21813917

Group type: EXPERIMENTAL
Intervention: Q-chews (4 chews providing 1,000 mg quercetin, 120 mg epigallocatechin 3-gallate, 400 mg isoquercetin, 400 mg each eicosapentaenoic acid and docosahexaenoic acid, 1,000 mg vitamin C, and 40 mg niacinamide)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo chews (PL)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Q-chews
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Exercise
Number of subjects: 20
Study: 19114542

Group type: EXPERIMENTAL
Intervention: levothyroxine (l-T(4)) replacement therapy
Number of subjects: 95
Study: 17031008

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (median dose: 200 IU/d)
Number of subjects: 1179

Group type: COMPARATOR
Intervention: No vitamin D supplementation
Number of subjects: 1179
Study: 15496646

Group type: EXPERIMENTAL
Intervention: Articaine HCl
Number of subjects: 0
Study: 10928305

Group type: EXPERIMENTAL
Intervention: ipsapirone (20 mg orally)
Number of subjects: 12

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study: 9298055

Group type: EXPERIMENTAL
Intervention: Undiluted vitreous
Number of subjects: 420

Group type: COMPARATOR
Intervention: Aqueous
Number of subjects: 420

Group type: COMPARATOR
Intervention: Vitrectomy cassette fluid
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Gram stain from aqueous or undiluted vitreous
Number of subjects: 420

Group type: COMPARATOR
Intervention: Vitrectomy
Number of subjects: 420
Study: 8342392

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (GH), 0.25 IU/kg/week for 6 months (0.125 IU/kg/week during the first month)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: recombinant human growth hormone (GH)
Number of subjects: 33

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 33
Study: 31192833

Group type: EXPERIMENTAL
Intervention: Auricular acupressure + counseling
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Placebo acupressure + counseling
Number of subjects: 55

Group type: COMPARATOR
Intervention: Self-help smoking cessation
Number of subjects: 55
Study: 28356053

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sodium valproate
Number of subjects: 62
Study: 26610874

Group type: EXPERIMENTAL
Intervention: Rivaroxaban
Number of subjects: 14236

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 14236
Study: 23848038

Group type: EXPERIMENTAL
Intervention: Bromocriptine
Number of subjects: 30
Study: 22016919

Group type: EXPERIMENTAL
Intervention: 1-step self-etch systems (ABSE 1-step)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2-step self-etch systems (ABSE 2-step)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clearfil S3 Bond (CS3)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Clearfil SE Bond (CSE)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Adper Prompt L-Pop (AD)
Number of subjects: 0
Study: 19690310

Group type: EXPERIMENTAL
Intervention: 6 mg oral estradiol (daily)
Number of subjects: 66

Group type: COMPARATOR
Intervention: 30 mg oral estradiol (daily)
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Estradiol-stimulated increase in fluorodeoxyglucose F 18 uptake
Number of subjects: 66
Study: 16476104

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg once daily)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Not specified
Number of subjects: 29
Study: 16296255

Group type: EXPERIMENTAL
Intervention: 0.45% stannous fluoride gel
Number of subjects: 30

Group type: COMPARATOR
Intervention: Colgate Total dentifrice slurry (0.30% triclosan, 0.24% sodium fluoride, 2% copolymer)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Dentifrice slurry without active ingredients
Number of subjects: 30
Study: 11505119

Group type: EXPERIMENTAL
Intervention: Enoximone
Number of subjects: 48

Group type: COMPARATOR
Intervention: Dobutamine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Both groups (Enoximone and Dobutamine)
Number of subjects: 48
Study: 9134472

Group type: EXPERIMENTAL
Intervention: Norton score
Number of subjects: 185

Group type: COMPARATOR
Intervention: Waterlow scale
Number of subjects: 185
Study: 20830883

Group type: EXPERIMENTAL
Intervention: Indirect composite resin restorations with cuspal coverage (buccal and palatal cusps reduced by 2 mm)
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Indirect composite resin restorations with only palatal cuspal coverage
Number of subjects: 4

Group type: COMPARATOR
Intervention: Indirect composite resin restorations (no cuspal coverage)
Number of subjects: 4
Study: 3538995

Group type: EXPERIMENTAL
Intervention: Theophylline + hydroxyzine (240 mg + 7.5 mg)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Theophylline monohydrate (281.7 mg)
Number of subjects: 15
Study: 30384932

Group type: EXPERIMENTAL
Intervention: Flash-free adhesive (APC Flash‐Free Adhesive Appliance System; 3M Unitek)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Conventional adhesive (APCII Adhesive Appliance System; 3M Unitek)
Number of subjects: 45
Study: 27113945

Group type: EXPERIMENTAL
Intervention: Periarticular liposomal bupivacaine injection
Number of subjects: 207

Group type: EXPERIMENTAL
Intervention: Periarticular injection of bupivacaine/morphine
Number of subjects: 207

Group type: COMPARATOR
Intervention: Intra-articular injection of bupivacaine/morphine
Number of subjects: 207
Study: 25733367

Group type: EXPERIMENTAL
Intervention: Auditory phoneme-based computer training program
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control group (no auditory training)
Number of subjects: 15
Study: 22416789

Group type: EXPERIMENTAL
Intervention: Lifestyle counselling from the nurse practitioner and the general practitioner
Number of subjects: 925

Group type: COMPARATOR
Intervention: Usual care (oral and written information)
Number of subjects: 925

Group type: EXPERIMENTAL
Intervention: Lifestyle counselling
Number of subjects: 925
Study: 20384435

Group type: EXPERIMENTAL
Intervention: B-type natriuretic peptide (BNP)
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Length of education
Number of subjects: 464

Group type: EXPERIMENTAL
Intervention: Diagnosis of hypertension
Number of subjects: 464
Study: 18534051

Group type: EXPERIMENTAL
Intervention: MAP0004 (orally-inhaled DHE)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 16798215

Group type: EXPERIMENTAL
Intervention: Bilateral stapled LVRS with buttressing technique
Number of subjects: 552

Group type: EXPERIMENTAL
Intervention: Patients with air leak
Number of subjects: 552

Group type: COMPARATOR
Intervention: Patients without air leak
Number of subjects: 552
Study: 12803268

Group type: EXPERIMENTAL
Intervention: Oral fentanyl (0.1 mg)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Oral midazolam (5 mg)
Number of subjects: 51
Study: 10816215

Group type: EXPERIMENTAL
Intervention: Automated electrogustometry testing on the right side of the tongue
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Automated electrogustometry testing on the left side of the tongue
Number of subjects: 97
Study: 8889350

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitor (enalapril)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Calcium channel blocker (amlodipine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Beta blocker (atenolol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure (goal MAP) of either 102-107 mm Hg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mean arterial blood pressure (goal MAP) of < or = 92 mm Hg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Renal biopsy (for participants without contraindication)
Number of subjects: 0
Study: 1893319

Group type: EXPERIMENTAL
Intervention: Standard DPT vaccine (25 Lf units of diphtheria toxoid)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Modified DPT vaccine (10 Lf units of diphtheria toxoid)
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Standard DPT vaccine
Number of subjects: 250

Group type: COMPARATOR
Intervention: Modified DPT vaccine
Number of subjects: 250
Study: 6678824

Group type: EXPERIMENTAL
Intervention: Dilazep, 300 mg daily
Number of subjects: 72

Group type: COMPARATOR
Intervention: Acetylsalicylic acid, 100 mg daily or dipyridamole, 300 mg daily
Number of subjects: 72
Study: 30975379

Group type: EXPERIMENTAL
Intervention: high DHA multi-nutrient supplement and exercise
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo supplement and exercise
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: high DHA multi-nutrient supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo supplement
Number of subjects: 0
Study: 28857263

Group type: EXPERIMENTAL
Intervention: BASE programme (Behaviour Analytics & Support Enhancement)
Number of subjects: 283

Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 283
Study: 27935924

Group type: EXPERIMENTAL
Intervention: Specific training on cessation techniques
Number of subjects: 1834

Group type: EXPERIMENTAL
Intervention: Role models for patients
Number of subjects: 1834

Group type: EXPERIMENTAL
Intervention: Routine advice to quit smoking
Number of subjects: 1834

Group type: EXPERIMENTAL
Intervention: Impact of tobacco use on advice
Number of subjects: 1834

Group type: EXPERIMENTAL
Intervention: Formal training on smoking cessation approaches
Number of subjects: 1834

Group type: EXPERIMENTAL
Intervention: Awareness of nicotine replacement therapies
Number of subjects: 1834

Group type: EXPERIMENTAL
Intervention: Attempts to quit smoking
Number of subjects: 1834
Study: 24127996

Group type: EXPERIMENTAL
Intervention: Cough and phlegm together
Number of subjects: 5887

Group type: EXPERIMENTAL
Intervention: Cough with phlegm
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Cough alone
Number of subjects: 5887

Group type: COMPARATOR
Intervention: Phlegm alone
Number of subjects: 5887
Study: 23052105

Group type: EXPERIMENTAL
Intervention: Problem-Solving Treatment (PST) delivered by mental health nurses
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC) by general practitioners
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Problem-Solving Treatment (PST)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cost-effectiveness analysis of PST
Number of subjects: 0
Study: 20943705

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin daily, starting on the first day of gonadotrophin stimulation until delivery
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo daily, starting on the first day of gonadotrophin stimulation until delivery
Number of subjects: 487

Group type: EXPERIMENTAL
Intervention: 100 mg aspirin
Number of subjects: 487

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 487
Study: 17382760

Group type: EXPERIMENTAL
Intervention: Spaced education (daily educational e-mails for 27 weeks)
Number of subjects: 537

Group type: COMPARATOR
Intervention: Bolus education (e-mailed a set of 96 study questions)
Number of subjects: 537
Study: 16181824

Group type: EXPERIMENTAL
Intervention: Milrinone, dobutamine, nitroglycerin, nitroprusside, nesiritide (established drugs approved by the FDA)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Levosimendan (REVIVE, CASINO, SURVIVE trials)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tezosentan (RITZ, VERITAS studies)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tolvaptan (ACTIV-CHF study)
Number of subjects: 0
Study: 12434608

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA)
Number of subjects: 40
Study: 10353374

Group type: EXPERIMENTAL
Intervention: Bilateral redundant targets
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Bilateral and within-field RTE
Number of subjects: 2
Study: 8756833

Group type: EXPERIMENTAL
Intervention: Salbutamol (300 micrograms)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study: 2008954

Group type: EXPERIMENTAL
Intervention: Butorphanol (7.1, 22.5, or 71.4 micrograms/kg)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Midazolam (4.3, 13.6, or 42.9 micrograms/kg)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Butorphanol and Midazolam combination (3.6 + 2.2, 11.3 + 6.8, or 35.7 + 21.5 micrograms/kg)
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: Butorphanol, Midazolam, and their combination
Number of subjects: 126
Study: 6193772

Group type: EXPERIMENTAL
Intervention: Argon laser photocoagulation
Number of subjects: 67

Group type: COMPARATOR
Intervention: Observation
Number of subjects: 67
Study: 31634868

Group type: EXPERIMENTAL
Intervention: Acupuncture (12 sessions, 30 min each for 4 weeks)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Celebrex (100 mg, 2 times daily)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 60

Group type: COMPARATOR
Intervention: Celebrex
Number of subjects: 60
Study: 31618520

Group type: EXPERIMENTAL
Intervention: Video education
Number of subjects: 205

Group type: COMPARATOR
Intervention: Control
Number of subjects: 205
Study: 28248850

Group type: COMPARATOR
Intervention: Iron-supplemented group (n=33)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Iron-supplemented combined erythropoietin group (n=32)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Control group (n=31)
Number of subjects: 96
Study: 25647754

Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo (control)
Number of subjects: 30
Study: 25035343

Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 5811

Group type: EXPERIMENTAL
Intervention: Vitamin E
Number of subjects: 5811

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5811
Study: 22658895

Group type: EXPERIMENTAL
Intervention: Intensive insulin therapy (glargine plus aspart)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Conventional therapy (control)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Molar insulin-to-C-peptide ratio (I/C) > 0.175
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Metformin and/or thiazolidinedione usage
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Age ≥ 60 years
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: I/C ≥ 0.175
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Average glucose level ≥ 180 mg/dL
Number of subjects: 52
Study: 19407666

Group type: EXPERIMENTAL
Intervention: L-methionine (1 g PO BID in phase 1 and 2 g PO BID in phase 2)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Placebo (placebo/placebo and placebo/L-methionine)
Number of subjects: 51